Search for: "Deas v. Deas" Results 1 - 20 of 797
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Jun 2025, 7:00 am by Jason Adelstone
If any such paraphernalia business is interested in challenging this policy, I would encourage them to do so – particularly in light of the Supreme Court’s decision in Loper Bright Enterprises v. [read post]
19 May 2025, 6:14 pm by Kurt R. Karst
Patients who repeatedly seek early fills of schedule II prescriptions or refills of schedule III-V prescriptions earlier than the date the drug would have run out if taken according to the prescriber’s instructions. ⁋⁋ 81, 89, 251. [read post]
21 Mar 2025, 11:02 am by Dr. Adam Feldman
DEA, where the court upheld the DEA’s denial of psilocybin use under the Controlled Substances Act. [read post]
7 Mar 2025, 12:30 pm by John Ross
So, we're happy to say that on April 29th the Supreme Court will hear Martin v. [read post]
11 Feb 2025, 10:53 am by usman
This schedule of drugs works much like the federal Drug Enforcement Agency’s (DEA) classification system. [read post]
10 Feb 2025, 7:27 am by Will Yeatman
DEA, a three-judge panel applied the Decker Coal doctrine in a short opinion that affirmed the DEA’s order against Dr. [read post]
3 Feb 2025, 7:30 pm by Liyun Huang and Thomas W. Greeson
During the COVID-19 PHE, the Ryan Haight Act’s in-person medical evaluation requirement was lifted under the fourth exception, thereby allowing DEA-registered practitioners to prescribe Schedule II-V controlled substances during audio-video telemedicine encounters and certain audio-only visits without requiring a prior in-person medical evaluation. [read post]
26 Jan 2025, 10:00 pm
Signaling a possible future approach to regulating Schedule II-V prescribing via telemedicine in lieu of in-person examinations, on January 17 the DEA issued a notice of proposed rulemaking regarding its next iteration of controlled substance prescribing controls. [read post]
26 Jan 2025, 10:00 pm
Signaling a possible future approach to regulating Schedule II-V prescribing via telemedicine in lieu of in-person examinations, on January 17 the DEA issued a notice of proposed rulemaking regarding its next iteration of controlled substance prescribing controls. [read post]